Previous 10 | Next 10 |
2023-08-10 12:25:36 ET Applied Therapeutics press release ( NASDAQ: APLT ): Q2 GAAP EPS of -$0.37. Cash and cash equivalents and short-term investments totaled $35.6 million as of June 30, 2023, compared with $30.6 million at December 31, 2022. For further details se...
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the FDA as well as EMA Marketing Authorization Application planned in Fall 2023 Phase 3 INSPIRE Trial of govorestat in Sorbitol Dehydrogenase (S...
2023-08-07 03:55:11 ET Summary Applied Therapeutics has experienced regular positive trial updates, frequent delays in NDA submission, and multiple dilutive stock offerings. The company's lead candidate, AT-007, showed a strong reduction in plasma galactitol but did not meet the F...
The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the safety and efficacy of AT-001 (caficrestat) in improving or preventing worsening of cardiac functional capacity in Diabetic Cardiomyopathy (DbCM); topline data from the study is expected in the fourth quarter of this year ...
Data further elucidates the pathophysiology of sorbitol toxicity, including sorbitol accumulation as the driver of disease in patient-derived motor neurons, as well as in the drosophila model and a new rat model of SORD Deficiency Clinical study data includes trial design, baseline data...
2023-05-25 07:49:29 ET The European Medicines Agency (EMA) granted orphan medicinal product designation to Applied Therapeutics' ( NASDAQ: APLT ) drug AT-007 (govorestat) to treat Sorbitol Dehydrogenase (SORD) Deficiency. SORD Deficiency is a rare hered...
EMA Orphan Designation reflects high unmet need in SORD Deficiency and benefit of govorestat treatment in reducing toxic sorbitol levels New data published in Journal of Clinical Investigation further elucidates the molecular pathophysiology of SORD neuropathy and the role of sorbitol in ...
2023-05-12 17:04:22 ET Applied Therapeutics ( NASDAQ: APLT ) has filed for a $300M mixed shelf securities offering. The filing does not necessarily indicate that a sale has begun or will occur in the future. The offering can include common stock, preferred stock, depositar...
2023-05-11 09:02:34 ET Applied Therapeutics press release ( NASDAQ: APLT ): Q1 GAAP EPS of -$0.18 beats by $0.25 . Cash and cash equivalents and short-term investments totaled $22.9 million as of March 31, 2023, compared with $30.6 million at December 31, 2022. F...
Demonstrated Long-term Clinical Benefit of Govorestat in ACTION-Galactosemia Kids Trial Strengthened Balance Sheet with $30 Million Private Placement of Equity Phase 3 INSPIRE Trial of Govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF Trial of AT-001 in Diabeti...
News, Short Squeeze, Breakout and More Instantly...
Applied Therapeutics Inc. Company Name:
APLT Stock Symbol:
NYSE Market:
Applied Therapeutics Inc. Website:
2024-07-27 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was adde...
2024-06-11 10:45:04 ET Palo Alto Networks Inc (PANW) PANW is trading UP for the last 5 days, and it at trading at $313.28 with volume of 858,188 and a one day change of $4.23 (1.37%). Palo Alto Networks Inc has a 52-week low of 201.17 and a 52-week high of $380.84. The business's 50...